GLP-1RAs linked to lower risk of amputation in diabetes with PAD

https://www.news-medical.net/news/20260710/GLP-1RAs-linked-to-lower-risk-of-amputation-in-diabetes-with-PAD.aspx The largest meta-analysis to date suggests GLP-1RAs may reduce major limb complications in people with type 2 diabetes and peripheral artery disease, although researchers say randomized trials are still needed to confirm a direct protective effect. A systematic review and meta-analysis published in the journal Cardiovascular Diabetology found that use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a significantly lower risk of major limb events in patients with type 2 diabetes and peripheral artery disease.